Barely a month passes without an announcement of improved survival rates for non-small cell lung cancer (NSCLC) patients. Much of this has been driven by favouring a personalised medicine approach over the historic “one size fits all” chemotherapy paradigm. Drugs…

Despite the impressive growth observed in China over the last two decades and with a projected healthcare market of RMB 8 trillion (USD 1.2 trillion), Chinese life science companies lag behind toptiered Western counterparts, both in terms of market capitalisation and…

On May 26th 2017, a new set of European Medical Device Regulations (“MDR”) and In Vitro Diagnostic Regulations (“IVDR”) entered into force. They represent a major overhaul and tightening of the previous directives and affect all companies marketing or developing…

Today the top ten best-selling antibody therapeutics for cancer have accumulated revenues approaching $200 Billion, the bulk of which is accounted for by sales of the four leading agents. Pharma is attracted to antibody deals in Oncology Download Request Name * First…

The term Nanotechnology refers to the domain of science and engineering that is applied to structures and materials that measure only a few billionths of a meter.  The term was coined by Japanese scientist Norio Taniguchi almost 40 years ago, and then popularised…

Pain management continues to face the dual hurdles of abuse of the most efficacious (opiod based) therapies and the difficulties of developing and commercialising new treatments. This challenging environment presents difficulties both for large pharmaceutical…

It’s easy to find trading and M&A multiples for mid and top tier CROs as their financial data are plentiful, often in the public domain and are the subject of discussion both in print and at conferences globally.  Although consolidation in this sector is often…

This presentation (available download on the left-hand side of this page) provides an overview of the EM opportunity, including some analysis of the financial performance of selected EM pharmaceutical industries and respective benchmark valuation metrics….

Policy-driven changes in healthcare spending and the growing significance of generic competition are acting in tandem to force pharmaceutical manufacturing companies to adopt more cost-effective manufacturing strategies resulting in an upsurge in the level of M&A…

In deal-making, options have long been considered a useful vehicle to carry uncertainty through to a point of resolution, or at least to a position of more understandable risk. Many very early stage players prefer the use of options to allow partners an opportunity to…

The incidence of co-promotion components in biotechnology/pharmaceutical licensing deals for development products has grown steadily since 1996 according to data from PharmaDeals© V4. In 1996 just 6% of licensing deals retained co-promotion rights or options for…

The growing threat of bacterial resistance is a high priority global issue with 193 countries signing a landmark UN General Assembly declaration calling for coordinated effort in this area. Without urgent action today’s routine infections could become killers and the…

The 25% rule of thumb is often quoted in the context of licensing deals royalty rates and in particular when deriving an appropriate rate of income due to a licensor for an innovative intellectual property asset. We have set out to conduct an in-depth…

With the growing understanding of numerous biologoical processes that are influenced by the 100 trillion microorganisms that make up the microbiome of an individual, there is an increasing number of Biotech and Pharma companies seeking to capitalize on this research…

Infection control is a crucial part of healthcare service delivery. Patients undergoing surgery need to be protected from infection during and after procedures. Surgical instruments are required to be cleaned and sterilised for re-use. The hospital environment needs…

In the 3rd quarter issue of termsheet last year, we predicted a significant increase in pharmaceutical M&A deal values for 2015. In our latest white paper ‘Trends in the CMO Landscape’ we demonstrate the impact this increase in deal values has had on the…

The pharmaceutical small molecule API manufacturing industry is now experiencing a period of rapid change. This change is being driven by factors such as the changing nature of the drugs being made, expiry of patents covering the top-selling pharmaceuticals, the…

In the last few years, pharmaceutical companies have become increasingly interested in biomarkers and their incorporation into company drug development programmes and use as companion tests for targeted therapeutics. Identifying patients that will benefit from a drug…

Deal making is the lifeblood of the pharmaceutical sector. In- and out-licensing and other types of agreements are key mechanisms by which intellectual property (IP) of innovative products and technologies is transferred between companies for achievement of…

The life sciences industry has never seen such an intensity of deal-making, especially that of licensing, than in the past six years. Some of the reasons for this are quite evident: growing pharmaceutical companies have greater pipeline needs, a spate of patent…

The late 1990s and early years of the current decade saw a number of mega-mergers between companies, which defined the current shape of the pharmaceutical industry, and have established a hierarchy of companies commonly referred to as `big pharma’. In recent years,…

The ophthalmology drug segment continues to shine brightly with a number of deals announced in November such as Genentech’s partnering with Novartis to split ex-US rights to Ophthotech’s eye drug, which could be worth more than $1 billion. Allergan,…

The ‘antibiotic crisis’ is rarely out of the news these days, with headlines issuing dire warnings that the rise in resistance to anti-microbial drugs could result in a return to the medical dark ages. In order to tackle this problem, various initiatives have been…

The ophthalmology device segment has experienced robust transaction activity with over 500 transactions taking place between January 2010 and the end of the first quarter in 2015. In this white paper we look at the range of transaction activity by type, geography and…

Leading CMOs are developing acquisition strategies based on reinforcing their customer base, expanding their geographic reach and broadening their capabilities. Similarly, customers are increasingly demanding simpler sourcing models that can deliver speed and…

Immuno-oncology is the latest and perhaps the most exciting development in cancer and immunotherapy. In this white paper we take a look at the history and the recent deal activity and at why we can expect this to be a hot area for deal making in the immediate future….

Deal-making is one of the key strategies employed by pharma companies to fuel growth opportunities. On a spectrum that ranges from intramural organic growth to extramural outright acquisitions, pharma deal-making occupies an intermediate position. One can easily argue…

It is not surprising that mostly small to medium sized companies seek the help of specialist consultancies to find commercial partners or find in-licensing opportunities. Large pharma are in the attractive position that they get thousands of unsolicited licensing…

It’s useful to review deal trends periodically to gain insight in how behaviours are changing from the perspective of numbers and value of deals as well as how emphasis shifts from one therapeutic area to another. The majority of small and mid-size development…